Intra-arterial peptide-receptor radionuclide therapy for neuro-endocrine tumour liver metastases: an in-patient randomised controlled trial (LUTIA).

ABSTRACT:

Purpose

Peptide receptor radionuclide therapy (PRRT) using [¹⁷⁷Lu]Lu-DOTATATE has been shown to effectively prolong progression free survival in grade 1-2 gastroenteropancreatic neuroendocrine tumours (GEP-NET), but is less efficacious in patients with extensive liver metastases. The aim was to investigate whether tumour uptake in liver metastases can be enhanced by intra-arterial administration of [¹⁷⁷Lu]Lu-DOTATATE into the hepatic artery, in order to improve tumour response without increasing toxicity.

Methods

Twenty-seven patients with grade 1-2 GEP-NET, and bi-lobar liver metastases were randomized to receive intra-arterial PRRT in the left or right liver lobe for four consecutive cycles. The contralateral liver lobe and extrahepatic disease were t

SUBMITTER: Ebbers SC 

PROVIDER: S-EPMC10881701 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature